DEFA14A: Dynavax Urges Stockholders to Vote FOR its Director Nominees Amid Deep Track Challenge

Dynavax is urging stockholders to vote for its four director nominees to protect the company's positive trajectory and long-term value against Deep Track's proposed changes.

Summary

• Dynavax is urging its stockholders to vote for its four director nominees at the upcoming Annual Meeting on June 11.
• The company highlights its strong performance, including a 203% return to stockholders over the last five years, outperforming vaccine peers and the S&P Biotechnology Select Industry Index.
• Dynavax's board believes that the current directors are essential to the company's success and that Deep Track's plan could jeopardize long-term stockholder value.
• The company encourages stockholders to vote using the GOLD proxy card and disregard any materials from Deep Track.

Sentiment

Score: 7

Explanation: The document expresses confidence in Dynavax's current strategy and board, while also conveying concern about the potential negative impact of Deep Track's involvement. The overall tone is assertive and persuasive, aiming to rally stockholder support.

Positives

• Dynavax has delivered strong returns to stockholders, outperforming its peers.
• The company emphasizes the expertise and strategic contributions of its director nominees.
• The board is focused on enhancing long-term value for all stockholders.
• Dynavax is one of the few vaccine companies that has returned meaningful capital to stockholders.

Negatives

• Deep Track is attempting to replace four critical members of the Dynavax Board.
• Deep Track's plan is viewed as a threat to the company's long-term value.
• The proxy battle introduces uncertainty and potential disruption to Dynavax's strategy.

Risks

• The outcome of the vote at the Annual Meeting could significantly impact the company's direction.
• There is a risk that Deep Track's plan could negatively affect Dynavax's long-term performance.
• The company's future growth and performance are subject to various risks and uncertainties, including those related to commercializing HEPLISAV-B and developing vaccines containing CpG 1018 adjuvant.

Future Outlook

The company's future growth, business strategy, and long-term performance are subject to risks and uncertainties, including those related to commercializing HEPLISAV-B and developing vaccines containing CpG 1018 adjuvant.

Management Comments

• The Dynavax Board of Directors is singularly focused on enhancing long-term value for all stockholders.
• We have the right Board, are successfully executing the right strategy and are delivering record financial and operational results.
• Do not let Deep Track derail Dynavaxs positive trajectory by replacing these four critical members of our Board with inferior candidates.
• Deep Track is entirely focused on implementing its one-dimensional plan to strip-mine Dynavax that will jeopardize long-term stockholder value.

Industry Context

The document highlights Dynavax's outperformance compared to its vaccine peers and the broader biotechnology industry, suggesting a competitive advantage or successful strategy within the sector. The proxy battle with Deep Track reflects a potential shift in control or strategic direction, which is a common occurrence in the biotechnology industry where companies are often targets for activist investors or acquisitions.

Comparison to Industry Standards

• Dynavax's 203% return to stockholders over the last five years significantly outperforms the average return of vaccine peers (9%) and the negative return of the S&P Biotechnology Select Industry Index (-17%).
• This suggests that Dynavax has been more successful in generating value for its shareholders compared to other companies in the vaccine and biotechnology sectors.
• Companies like Moderna and BioNTech, which experienced rapid growth during the COVID-19 pandemic, may have higher returns over shorter periods, but Dynavax's sustained performance over five years indicates a more stable and consistent growth trajectory.

Stakeholder Impact

• The outcome of the proxy vote will impact shareholders by influencing the company's strategic direction and potential value creation.
• Employees may be affected by changes in leadership or strategy resulting from the proxy vote.
• The company's relationships with customers and suppliers could be impacted by any shifts in business strategy.

Next Steps

• Stockholders need to vote on the director nominees before the Annual Meeting on June 11.
• The company will continue to engage with stockholders to advocate for its director nominees.

Key Dates

Keywords

Dynavax, stockholders, Deep Track, proxy vote, director nominees, Annual Meeting, HEPLISAV-B, vaccine, stockholder value, board of directors